Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005;23(9):1147- 57. Abstract

Albain KS et al. Global phase III study of gemcitabine plus paclitaxel (GT) vs paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall survival. Proc ASCO 2004;Abstract 510.

Choueiri TK et al. Role of aromatase inhibitors in the treatment of breast cancer. Clin Ther 2004;26(8):1199-214. Abstract

Cobleigh MA et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003;30(5 Suppl 16):117-24. Abstract

Franco S et al. Response to fulvestrant in heavily pretreated postmenopausal women: A single-center experience. Breast Cancer Res Treat 2004;88(2):103-8. Abstract

Gralow JR. Optimizing the treatment of metastatic breast cancer. Breast Cancer Res Treat 2005;89(Suppl 1):9-15. Abstract

Howell SJ et al. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer. Best Pract Res Clin Endocrinol Metab 2004;18(1):47-66. Abstract

Hussain SA et al. Endocrine therapy and other targeted therapies for metastatic breast cancer. Expert Rev Anticancer Ther 2004;4(6):1179-95. Abstract

Hudis CA. Clinical implications of antiangiogenic therapies. Oncology (Williston Park) 2005;19(4 Suppl 3):26-31. Abstract

Ignoffo RJ. Overview of bevacizumab: A new cancer therapeutic strategy targeting vascular endothelial growth factor. Am J Health Syst Pharm 2004;61(21 Suppl 5):21-6. Abstract

Janicke F. Are all aromatase inhibitors the same? A review of the current evidence. Breast 2004;13(Suppl 1):10-8. Abstract

Miller KD et al. E2100: A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer. Presentation. ASCO 2005a. No abstract available

Miller KD et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005b;23(4):792-9. Abstract

O’Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist 2005;10(Suppl 3):20-9. Abstract

O’Shaughnessy J et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 2002;20(12):2812-23. Abstract

Pegram MD et al. Phase I combined biological therapy of breast cancer using two humanized monoclonal antibodies directed against HER2 proto-oncogene and vascular endothelial growth factor (VEGF). San Antonio Breast Cancer Symposium 2004;Abstract 3039.

Pippen J et al. Fulvestrant (Faslodex) versus anastrozole (Arimidex) for the treatment of advanced breast cancer: A prospective combined survival analysis of two multicenter trials. Poster. San Antonio Breast Cancer Symposium 2003;Abstract 426.

Rhee J, Hoff PM. Angiogenesis inhibitors in the treatment of cancer. Expert Opin Pharmacother 2005;6(10):1701-11. Abstract

Rieber AG, Theriault RL. Aromatase inhibitors in postmenopausal breast cancer patients. J Natl Compr Canc Netw 2005;3(3):309-14. Abstract

Robertson JF et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: A prospective combined analysis of two multicenter trials. Cancer 2003;98(2):229-38. Abstract

Sledge GW et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: An intergroup trial (E1193). J Clin Oncol 2003;21(4):588-92. Abstract

Slimane K et al. Risk factors for brain relapse in patients with metastatic breast cancer. Ann Oncol 2004;15(11):1640-4. Abstract

Sundar S et al. Management of endocrine resistant breast cancer. J Br Menopause Soc 2004;10(1):16-23. Abstract